INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50901, 29905, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50902, 29906, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50903, 2521, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50904, 16268, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50905, 16274, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50906, 18760, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50907, 18761, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50908, 22080, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50909, 29905, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50910, 29906, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50911, 2521, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50912, 16268, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50913, 16274, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50914, 18760, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50915, 18761, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50916, 22080, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50917, 29905, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50918, 29906, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50919, 0, 'Factor XIII (human)', 'Thromboembolism', 'Thromboembolic complications have been reported after therapy with factor XIII, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50920, 0, 'Factor IX Complex (Human)', 'Thromboembolism', 'The use of factor IX complex concentrates has been associated with the development of thromboembolic complications.  Patients at increased risk for thrombosis include those undergoing surgery, post surgery, with known liver disease, and with signs of fibrinolysis, thrombosis, or disseminated intravascular coagulation.  When administering factor IX complex to these high-risk patients, monitor for early signs of consumptive coagulopathy with appropriate laboratory testing.  Only administer factor IX complex to patients when the benefits outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50921, 0, 'Aminoglutethimide', 'Adrenal Insufficiency', 'Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing''s syndrome.  It generally should not be used in patients with adrenocortical insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50922, 0, 'Fenfluramine', 'Heart Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine have been associated with valvular heart disease.  Exercise care when using this agent in patients with cardiac disease.  Cardiac monitoring is required prior to starting, during, and after treatment.  If valvular heart disease is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50923, 0, 'Fenfluramine', 'Lung Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine, have been associated with pulmonary arterial hypertension.  Exercise care when using this agent in patients with pulmonary disease.  Cardiac monitoring is required before starting, during, and after treatment.  Cardiac monitoring via echocardiogram can identify evidence of pulmonary arterial hypertension.  If pulmonary arterial hypertension is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50924, 0, 'Fenfluramine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50925, 0, 'Fenfluramine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50926, 0, 'Fenfluramine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50927, 0, 'Fenfluramine', 'Alcoholism', 'Fenfluramine can cause somnolence, sedation, and lethargy.  Central nervous system depressants, including alcohol, could potentiate these effects.  Exercise caution when using this agent in alcoholic patients or those at risk of sedation.  Close monitoring is advised.  Advise patients not to drive or operate machinery until they know how this drug will affect them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50928, 0, 'Fenfluramine', 'Anorexia', 'Fenfluramine can cause decreases in appetite and weight.  Exercise care when using this agent in patients at risk of decreased appetite or weight.  It is recommended to monitor the growth of pediatric patients carefully.  Weight should be monitored regularly during treatment, and dose modifications should be considered if a decrease in weight is observed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50929, 0, 'Fenfluramine', 'Hypertension', 'Fenfluramine can cause an increase in blood pressure.  Exercise care when using this agent in hypertensive patients.  It is recommended to monitor blood pressure in patients treated with fenfluramine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50930, 0, 'Fenfluramine', 'Liver Failure', 'Fenfluramine is primarily metabolized to norfenfluramine by CYP450 1A2, CYP450 2B6, and CYP450 2D6.  The use of fenfluramine in patients with hepatic impairment is not recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50931, 0, 'Fenfluramine', 'Kidney Diseases', 'Most of an orally administered dose of fenfluramine (greater than 90%) is excreted in the urine as fenfluramine, norfenfluramine, or other metabolites.  The use of fenfluramine in patients with moderate or severe renal impairment is not recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50932, 0, 'Fenfluramine', 'Vision Disorders', 'Fenfluramine can cause mydriasis and can precipitate angle-closure glaucoma.  Exercise care when using this agent in patients with visual disturbances.  Consider discontinuing treatment in patients with acute decrease in visual acuity or ocular pain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50933, 727, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50934, 4751, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50935, 4752, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50936, 7996, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50937, 11962, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50938, 12664, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50939, 12665, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50940, 17824, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50941, 17825, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50942, 18099, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50943, 18890, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50944, 18892, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50945, 19827, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50946, 20026, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50947, 20027, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50948, 27484, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50949, 27485, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50950, 27486, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50951, 28793, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50952, 28794, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50953, 28843, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50954, 28844, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50955, 29713, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50956, 29714, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50957, 29715, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50958, 30137, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50959, 30613, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50960, 30614, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50961, 31533, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50962, 32311, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50963, 727, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50964, 4751, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50965, 4752, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50966, 7996, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50967, 11962, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50968, 12664, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50969, 12665, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50970, 17824, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50971, 17825, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50972, 18099, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50973, 18890, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50974, 18892, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50975, 19827, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50976, 20026, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50977, 20027, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50978, 27484, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50979, 27485, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50980, 27486, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50981, 28793, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50982, 28794, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50983, 28843, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50984, 28844, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50985, 29713, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50986, 29714, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50987, 29715, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50988, 30137, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50989, 30613, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50990, 30614, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50991, 31533, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50992, 32311, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50993, 727, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50994, 4751, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50995, 4752, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50996, 7996, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50997, 11962, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50998, 12664, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50999, 12665, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51000, 17824, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
